hlx22
mAbexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started May 31, 2019 (NCT03916094)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07294508 | Phase 2/Phase 3 (Phase 3) | Jan 25, 2026 | Shanghai Henlius Biotech |
| NCT07176702 | Phase 2 | Sep 30, 2025 | Fudan University |
| NCT06832202 | Phase 2 | Mar 31, 2025 | Shanghai Henlius Biotech |
| NCT06532006 | Phase 3 | Nov 1, 2024 | Shanghai Henlius Biotech |
| NCT04908813 | Phase 2 | Oct 31, 2021 | Shanghai Henlius Biotech |
| NCT03916094 | Phase 1 | May 31, 2019 | Jilin University, Shanghai Henlius Biotech |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Henlius Biotech | For profit | 5 | 5 | 3 | 2019 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Jilin University | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1